Serum interleukin 6 as a prognostic factor in patients with prostate cancer

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2702-2706

  Nakashima, Jun ^a   Tachibana, Masaaki ^a   Horiguchi, Yutaka ^a   Oya, Mototsugu ^a   Ohigashi, Takashi ^a   Asakura, Hirotaka ^a   Murai, Masaru ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; HEMOGLOBIN; INTERLEUKIN 6; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; HEMOGLOBINS; HUMANS; INTERLEUKIN-6; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0033911711     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kishimoto, T. The biology of interleukin-6. Blood, 74: 1-10, 1989.
2. Le, J. M., and Vilcek, J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab. Invest., 61: 588-602, 1989.
3. Wolvekamp, M. C., and Marquet, R. L. Interleukin-6: historical background, genetics and biological significance. Immunol. Lett., 24: 1-9, 1990.
4. Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W. S., Kim, W. Y., and Simons, J. W. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology, 45: 542-549, 1995.
5. Adler, H. L., McCurdy, M. A., Kattan, M. W., Timme, T. L., Scardino, P. T., and Thompson, T. C. Elevated levels of circulating inteleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J. Urol., 161: 182-187, 1999.
6. Soloway, M. S., Hardeman, S. W., Hickey, D., Raymond, J., Todd, B., Soloway, S., and Moinuddin, M., Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer (Phila.), 61: 195-202, 1988.
7. Okamoto, M., Lee, C., and Oyasu, R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res., 57: 141-146, 1997.
8. Tanner, J., and Tosato, G. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J. Clin. Invest., 88: 239-247, 1991.
9. Snick, J. V. Interleukin-6: an overview. Annu. Rev. Immunol., 8: 253-278, 1990.
10. De Vita, F., Orditura, M., Auriemma, A., Infusino, S., Roscigno, A., and Catalano, G. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol. Rep., 5: 649-652, 1998.
11. Blay, J. Y., Negrier, S., Combaret, C., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J. M., Moskovtchenko, J. F., Philip, T., and Favrot, M. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res., 52: 3317-3322, 1992.
12. Ljungberg, B., Grankvist, K., and Rasmuson, T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur. J. Cancer, 33: 1794-1798, 1997.
13. Plante, M., Rubin, S. C., Wong, G. Y., Federici, M. G., Finstad, C. L., and Gastl, G. A. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer (Phila.), 73: 1882-1888, 1994.
14. Scambia, G., Testa, U., Panici, P. B., Martucci, R., Foti, E., Gadducci, A., Perillo, A., Facchini, V., Peschle, C., and Mancuso, S. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br. J. Cancer, 71: 354-356, 1995.
15. Oka, M., Yamamoto, K., Takahashi, M., Hakozaki, M., Abe, T., lizuka, N., Hazama, S., Hirazawa, K., Hayashi, H., Tangoku, A., Hirose, K., Ishihara, T., and Suzuki, T. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res., 56: 2776-2780, 1996.
16. Imai, K., Yomaru, Y., Ohnuki, T., Yamanaka, H., Sakai, H., Kanetake, H., Minami, Y., Nomata, K., and Saito, Y. Significance of a new stratification of alkaline phosphatase and extent of disease in patients with prostate cancer with bone metastasis. Cancer (Phila.), 69: 2983-2989, 1992.
17. Matzkin, H., Soloway, M. S., Schellhammer, P. F., Chodak, G., Smith, J. A., Caplan, R., and Kennealey G. T. Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen. Cancer (Phila.), 72: 1286-1290, 1993.
18. Chodak, G. W., Vogelzang N. J., Caplan, R. J., Soloway, M., and Smith, J. A., for the Zoladex Study Group. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. J. Am. Med. Assoc., 265: 618-621, 1991.
19. Johansson, J. E., Andersson, S. O., Holmberg, L., and Bergstrom, R. Prognostic factors in progression-free survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens. J. Urol., 146: 1327-1332, 1991.
20. Ishikawa, S., Soloway, M. S., Van Der Zwaag, R., and Todd, B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J. Urol., 141: 1139-1142, 1989.
21. Castell, J. V., Gomez-Lechon, M. J., David, M., Hirano, T., Kishimoto, T., and Heinrich, P. C. Recombinant human interleukin-6 (IL-6/ BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett., 232: 347-350, 1988.
22. Johansson, J. E., Sigurdsson, T., Holmberg, L., and Bergstrom, R. Erythrocyte sedimentation rate as a tumor marker in human prostatic cancer. An analysis of prognostic factors in 300 population-based consecutive cases. Cancer (Phila.), 70: 1556-1563, 1992.